Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CTKB vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CTKB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)

CTKB Overall Winner 6-Pillar Tally: CTKB 4 – 2 MYO Matrix Metrics: CTKB 5 – 3 MYO

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CTKB carries a Unified Composite Score of 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.71β · 67% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CTKB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 56.9); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CTKB vs MYO
CTKB NASDAQ Head-to-Head Winner
Cytek Biosciences, Inc. Common Stock
Laboratory Analytical Instruments
$6.12
-3.16% 1D
Market Cap $826.6M
TTM Revenue $208M
Forward P/E N/M
Beta / 30D Vol 0.71β · 67% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 44.0 Flow 60.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.6% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $5.89 · SMA50: $5.63
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (CTKB 4 – 2 MYO)

Columns: Metric · CTKB · MYO
1. Valuation Multiples MYO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.8x 0.9x
2. Growth & Scale CTKB
Revenue Growth (YoY) +1.8% +22.2%
Earnings Growth (YoY) +73.5% +0.0%
TTM Revenue (USD) $208M $46M
Market Cap $826.6M $33.7M
3. Profitability & Quality MYO
Gross Margin 53.4% 70.1%
Operating Margin -22.5% -21.8%
Net Profit Margin -39.1% -33.1%
Return on Equity (ROE) -23.2% -173.5%
4. Balance Sheet & Cash Flow CTKB
Cash Generation (TTM) -$14M -$9.1M
Cash Flow Margin -6.6% -20.0%
Net Cash / Leverage $42M Net Cash $8.9M Net Debt (3.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CTKB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 0.1% (<1st %ile) 266.0% (81st %ile)
Put/Call OI Skew 0.03x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CTKB
OpEx & R&D Intensity 75.9% of Rev ($158M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CTKB (5) vs MYO (3)
Institutional Metric CTKB MYO Criterion Row Edge
Market Capitalization
Scale
$826.6M $33.7M Larger Scale CTKB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1.8% +22.2% Higher Growth MYO
Operating Margin (TTM)
Profitability
-22.5% -21.8% Higher Margin MYO
Net Profit Margin
Profitability
-39.1% -33.1% Higher Margin MYO
Return on Equity (ROE)
Capital Efficiency
-23.2% -173.5% Higher ROE CTKB
52-Week Range Position
Momentum
91% ($3–$6) 16% ($1–$2) Stronger Trend CTKB
Beta / 30D Volatility
Risk Regime
0.71β · 67% Vol 2.22β · 107% Vol Lower Realized Risk CTKB
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite CTKB
Trailing 12M Revenue (USD)
Operating Scale
$208M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.4% 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.8x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$14M ($42M Net Cash) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CTKB +46.23 pp
CTKB: +12.71% · MYO: -33.52%
3M Horizon CTKB +79.49 pp
CTKB: +37.84% · MYO: -41.65%
6M Horizon CTKB +74.64 pp
CTKB: +52.62% · MYO: -22.02%
1Y Horizon CTKB +4.05 pp
CTKB: +16.35% · MYO: +12.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CTKB Revenue MYO Revenue CTKB Op. Margin MYO Op. Margin Margin Leader
FY2018 N/A $0M N/A -430.8% MYO
FY2019 N/A $0M N/A -281.3% MYO
FY2020 $90M $10M 14.7% -138.5% CTKB
FY2021 $130M $10M 7.2% -74.1% CTKB
FY2022 $160M $20M -1.1% -68.6% CTKB
FY2023 $190M $20M -14.4% -42.8% CTKB
FY2024 $200M $30M -10.2% -19.1% CTKB
FY2025 $200M $40M -20.0% -35.2% CTKB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CTKB CONSOLIDATION
16d in phase · OBV ACCUMULATION
Current IV 0.1%
IV Percentile <1st %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CTKB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CTKB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $826.6M market capitalization and -22.5% operating margin.
OpEx & R&D Reinvestment 75.9% of Rev ($158M)
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CTKB vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CTKB carries a Unified Composite Score of 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.71β · 67% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CTKB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 56.9); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CTKB leads the Growth & Scale pillar: CTKB posts +1.8% YoY revenue growth and +73.5% YoY earnings growth on $208M TTM revenue (53.4% gross margin, -22.5% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CTKB cumulative revenue shifted +122.2% while MYO shifted +300.0%. In operating R&D and SG&A reinvestment, CTKB deploys 75.9% of Rev ($158M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

MYO screens cheaper on headline valuation multiples. CTKB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.8x EV/Revenue (-6.6% FCF margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CTKB (-23.2% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CTKB carries 0.1% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 67% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.